Experimental IPF Therapies: Cotrimoxazole

0
(0)

pf_experimental

Cotrimoxazole (Trisulfa-FPI) is a combination of trimethoprim and sulfamethoxazole in fixed amounts (trimethoprim 80 mg and sulfamethoxazole 400 mg) used to treat bacterial, fungal and protozoal infections. It is developed and marketed worldwide with different brand names including Septra (GlaxoSmithKline plc) and Bactrim (Hoffmann-La Roche). Being a broad spectrum antibiotic, it also finds uses in other diseases where infections are secondary. Idiopathic Pulmonary Fibrosis (IPF) is one such disease where cotrimoxazole is being used as a therapeutic option.

 

Learn more about Cotrimoxazole: http://bit.ly/1WXaS1u

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *